Clinical impact of FDG‐PET/CT in the planning of radiotherapy for early‐stage Hodgkin lymphoma
- 19 December 2006
- journal article
- clinical trial
- Published by Wiley in European Journal of Haematology
- Vol. 78 (3), 206-212
- https://doi.org/10.1111/j.1600-0609.2006.00802.x
Abstract
Early-stage Hodgkin lymphoma (HL) has excellent survival rates but carries a high risk of late treatment-related adverse effects. Modern, individualised therapeutic strategies require an accurate determination of the extent of the disease. This study investigated the potential impact of 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography/computerised tomogrpahy (FDG-PET/CT) in the planning of involved field radiotherapy (IFRT). Thirty patients received staging FDG-PET/CT before therapy, and IFRT after a short course of ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy. IFRT planning was performed using only the CT data from the FDG-PET/CT scan. Later, the IFRT planning was performed anew using the FDG-PET/CT data as basis for contouring. In 20 out of 30 patients, the radiotherapy (RT) course was unaffected by the addition of FDG-PET/CT. FDG-PET/CT would have increased the irradiated volume in seven patients where the volume receiving a minimum of 90% of the target dose was increased by 8-87%. FDG-PET/CT decreased the volume in two patients where the volume was reduced by 18% and 30%. When used for RT planning, FDG-PET/CT results in larger IFRT treatment volumes. If FDG-PET/CT is introduced to RT planning, the method should be accompanied by a change in RT treatment strategy, aiming at more targeted therapy in order to best avoid radiation to normal tissues.Keywords
This publication has 24 references indexed in Scilit:
- Site of relapse after chemotherapy alone for stage I and II Hodgkin's diseaseRadiotherapy and Oncology, 2006
- Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin’s disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?International Journal of Radiation Oncology*Biology*Physics, 2006
- FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphomaBlood, 2006
- Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphomaAnnals of Oncology, 2005
- Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphomaRadiotherapy and Oncology, 2004
- Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's diseaseAnnals Of Oncology, 2004
- Impact of FDG-PET on radiation therapy volume delineation in non–small-cell lung cancerInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s DiseaseJournal of Clinical Oncology, 2003
- Long-term complications of treatment and causes of mortality after Hodgkin's diseaseSeminars in Radiation Oncology, 1996
- Breast Cancer and Other Second Neoplasms after Childhood Hodgkin's DiseaseNew England Journal of Medicine, 1996